SCHEMBL22984901

SCHEMBL22984901

CC(C)c1cc(Cl)c(Cl)cc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
PDE2A O00408 2/20 0.39
P2RX7 Q99572 1/20 0.39
NOTUM Q6P988 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
KDM4E B2RXH2 1/20 0.33
AR P10275 1/20 0.32
TRPA1 O75762 1/20 0.32
EIF4A3 P38919 1/20 0.32
HTR2A P28223 1/20 0.31
SLC6A4 P31645 1/20 0.31
KCNH2 Q12809 1/20 0.31
PTGS2 P35354 1/20 0.31
RAPGEF4 Q8WZA2 1/20 0.31
PDK1 Q15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24868586 0.89 PDE2A (0.42) LMNAPDE2AP2RX7NOTUMAKR1C3
SCHEMBL23625165 0.84 NOTUM (0.40) PDE2AP2RX7NOTUMGABRA1GABRB1
SCHEMBL24165388 0.81 NOTUM (0.39) PDE2AP2RX7NOTUMGABRA1GABRB1
SCHEMBL11604200 0.80 P2RX7 (0.32) PDE2AP2RX7NOTUMAKR1C3AKR1C2
SCHEMBL20690300 0.80 LMNA (0.41) LMNAGABRA1GABRB1KDM4E
SCHEMBL24985319 0.78 PDE2A (0.40) LMNAPDE2AP2RX7NOTUMAKR1C3
SCHEMBL12303919 0.77 PDE2A (0.42) LMNAPDE2AP2RX7NOTUMAKR1C3
SCHEMBL24986401 0.76 PDE2A (0.39) LMNAPDE2AP2RX7GABRA1GABRB1
SCHEMBL24946314 0.76 LMNA (0.56) LMNAPDE2AP2RX7GABRA1GABRB1
SCHEMBL16736892 0.76 LMNA (0.47) LMNAPDE2AP2RX7AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919850-B2 Covalent inhibitors of KRas G12C ARAXES PHARMA LLC (US) 2021-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919850-B2 Covalent inhibitors of KRas G12C KRAS, NRAS, HRAS LMNA 3439/4885PDE2A 4096/4885P2RX7 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.